C90.00
BillableMultiple myeloma not having achieved remission
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is C90.00 an HCC code?
Yes. C90.00 maps to Lymphoma and Other Cancers under the CMS-HCC V28 risk adjustment model (and Lung and Other Severe Cancers under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C90.00
For C90.00 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C90.00 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
C90.00 is the ICD-10-CM diagnosis code for multiple myeloma not having achieved remission. Multiple myeloma, a cancer of plasma cells in the bone marrow, that has not responded to treatment or is still active. C90.00 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).
Under the CMS-HCC V28 risk adjustment model, C90.00 maps to Lymphoma and Other Cancers (HCC 19) with a community, non-dual, aged base RAF weight of 0.105. Under the older CMS-HCC V24 model, C90.00 maps to Lung and Other Severe Cancers (HCC 9) with a community, non-dual, aged base RAF weight of 0.973. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Multiple myeloma is the most common type of immunoproliferative disease; fifth character indicates remission status. Because C90.00 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C90.00 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Multiple myeloma is the most common type of immunoproliferative disease; fifth character indicates remission status
- •Document whether patient has achieved remission, is in relapse, or has not achieved remission for accurate coding
Clinical Significance
Multiple myeloma is the most common plasma cell neoplasm, characterized by malignant proliferation of plasma cells in the bone marrow producing monoclonal immunoglobulin that causes end-organ damage including renal failure, anemia, hypercalcemia, and lytic bone lesions (CRAB criteria). Non-remission status indicates the disease remains active and is causing or at risk for causing these complications. Multiple myeloma requires ongoing treatment to prevent disease progression and organ damage.
Documentation Requirements
- ✓Documentation must include bone marrow biopsy confirming plasma cell percentage, serum and urine protein electrophoresis with immunofixation, free light chain ratio, skeletal survey or PET-CT for bone lesions, and assessment of CRAB criteria.
- ✓Disease stage (ISS or R-ISS), treatment regimen, response assessment using IMWG criteria, and explicit non-remission status are required.